- |||||||||| Tecfidera (dimethyl fumarate) / Biogen, Plegridy (PEG-interferon β-1a) / Biogen
The fiscal consequences of public health investments in disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis in Sweden (Poster Exhibition) - Aug 28, 2019 - Abstract #ECTRIMS2019ECTRIMS_844; Methods : We applied disease progression rates from previous MS Markov cohort models over 30-years for intramuscular interferon beta-1a, peginterferon beta-1a, dimethyl fumarate and natalizumab using a modified generational accounting modeling framework...Discussion : The analysis described here highlights the broader public economic benefits for government attributed to changes in disease status. These findings suggest that focusing cost-effectiveness analysis only on health costs will likely underestimate the value of DMTs.
- |||||||||| Tecfidera (dimethyl fumarate) / Biogen, Plegridy (PEG-interferon β-1a) / Biogen
Reimbursement, Journal, Medicare: Trends in Prices, Market Share, and Spending on Self-administered Disease-Modifying Therapies for Multiple Sclerosis in Medicare Part D. (Pubmed Central) - Aug 27, 2019 ...All prescription claims for self-administered DMTs for MS (glatiramer acetate, interferon beta-1a, interferon beta-1b, fingolimod hydrochloride, teriflunomide, dimethyl fumarate, and peginterferon beta-1a) were extracted throughout the study period...Platform therapies experienced a substantial drop from 2006 to 2016 in favor of newer therapies, with decreases in the market shares of brand-name glatiramers (per 1000 Medicare beneficiaries: $2861 of $7794 [36.7%] to $25 552 of $79 411 [32.2%]), interferon beta-1a (30 µg; per 1000 Medicare beneficiaries: $2521 of $7794 [32.3%] to $11 298 of $79 411 [14.2%]), interferon beta-1b (Betaseron; per 1000 Medicare beneficiaries: $1460 of $7794 [18.7%] to $3588 of $79 411 [4.5%]), and interferon beta-1a (8.8/22/44 µg; per 1000 Medicare beneficiaries: $951 of $7794 [12.2%] to $6588 of $79 411 [8.3%]) and increases in fingolimod (to $6311 of $79 411 per 1000 Medicare beneficiaries [7.9%]), teriflunomide (to $7177 of $79 411 per 1000 Medicare beneficiaries [9.0%]), and dimethyl fumarate (to $15 262 of $79 411 per 1000 Medicare beneficiaries [19.2%])...Per this analysis, prices of self-administered DMTs for MS increased dramatically between 2006 and 2016. This resulted in a 7.2-fold increase in patient out-of-pocket costs.
- |||||||||| Plegridy (PEG-interferon β-1a) / Biogen
Trial completion date, Trial primary completion date, Adverse events: Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects (clinicaltrials.gov) - Aug 14, 2019 P4, N=50, Recruiting, This resulted in a 7.2-fold increase in patient out-of-pocket costs. Trial completion date: Jul 2018 --> May 2020 | Trial primary completion date: Jun 2018 --> May 2020
- |||||||||| Journal: Siponimod (Mayzent)--a new drug for multiple sclerosis. (Pubmed Central) - Aug 6, 2019
This report addresses expert recommendations on the management of most relevant adverse effects related to peginterferon beta-1a and other interferon betas, based on literature and interdisciplinary experience. No abstract available
- |||||||||| Plegridy (PEG-interferon β-1a) / Biogen
Journal: Localized pigmentation disorder after subcutaneous pegylated interferon beta-1a injection. (Pubmed Central) - Jul 24, 2019 After 6 months, the lesions had worsened. This is the first case of localized pigmentation disorder reported with interferon beta, and while the clinical findings are not ascribable to vitiligo or interferon-related facial/mucosal hyperpigmentation, they may partially share the underlining mechanisms.
- |||||||||| Betaseron (IFN-β-1b) / Bayer
Trial completion, Trial completion date, Trial initiation date, Trial primary completion date: EPID Multiple Sclerosis Pregnancy Study (clinicaltrials.gov) - Sep 4, 2018 P=N/A, N=1671, Completed, Not yet recruiting --> Recruiting | Initiation date: Oct 2018 --> Jan 2019 | Trial primary completion date: Sep 2022 --> Dec 2022 Recruiting --> Completed | Trial completion date: May 2019 --> Aug 2018 | Initiation date: Apr 2017 --> May 2016 | Trial primary completion date: Jan 2019 --> Aug 2018
- |||||||||| Plegridy (PEG-interferon β-1a) / Biogen
Trial completion date, Trial primary completion date: PLENO: Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy (clinicaltrials.gov) - Jul 20, 2018 P4, N=140, Recruiting, Recruiting --> Completed | Trial completion date: May 2019 --> Aug 2018 | Initiation date: Apr 2017 --> May 2016 | Trial primary completion date: Jan 2019 --> Aug 2018 Trial completion date: Dec 2018 --> Mar 2020 | Trial primary completion date: Dec 2018 --> Mar 2020
- |||||||||| Betaseron (IFN-β-1b) / Bayer
Trial completion date, Trial primary completion date: EPID Multiple Sclerosis Pregnancy Study (clinicaltrials.gov) - May 30, 2018 P=N/A, N=1671, Recruiting, Trial completion date: Dec 2018 --> Mar 2020 | Trial primary completion date: Dec 2018 --> Mar 2020 Trial completion date: Apr 2018 --> May 2019 | Trial primary completion date: Apr 2018 --> Jan 2019
- |||||||||| Plegridy (PEG-interferon β-1a) / Biogen
Trial completion: PLATINUM: Plegridy Satisfaction Study in Participants (clinicaltrials.gov) - Apr 18, 2018 P4, N=199, Completed, Trial completion date: Apr 2018 --> May 2019 | Trial primary completion date: Apr 2018 --> Jan 2019 Active, not recruiting --> Completed
- |||||||||| Betaseron (IFN-β-1b) / Bayer
Trial primary completion date: EPID Multiple Sclerosis Pregnancy Study (clinicaltrials.gov) - Nov 18, 2017 P=N/A, N=1671, Recruiting, Recruiting --> Active, not recruiting | N=60 --> 23 Trial primary completion date: Oct 2017 --> Apr 2018
- |||||||||| Plegridy (PEG-interferon β-1a) / Biogen
Enrollment closed, Enrollment change: PLATINUM: Plegridy Satisfaction Study in Participants (clinicaltrials.gov) - Sep 19, 2017 P4, N=199, Active, not recruiting, Trial primary completion date: Oct 2017 --> Apr 2018 Recruiting --> Active, not recruiting | N=275 --> 199 | Recruiting --> Active, not recruiting | N=275 --> 199
- |||||||||| Betaseron (IFN-β-1b) / Bayer
Trial initiation date: EPID Multiple Sclerosis Pregnancy Study (clinicaltrials.gov) - Jun 15, 2017 P=N/A, N=1671, Recruiting, Phase classification: P=N/A --> P4 Initiation date: May 2016 --> Apr 2017 | Trial primary completion date: Apr 2017 --> Oct 2017 | Initiation date: May 2016 --> Apr 2017
- |||||||||| Plegridy (PEG-interferon β-1a) / Biogen
Trial primary completion date: PLATINUM: Plegridy Satisfaction Study in Participants (clinicaltrials.gov) - May 16, 2017 P4, N=275, Recruiting, Not yet recruiting --> Recruiting Trial primary completion date: Jun 2017 --> Dec 2017
- |||||||||| Plegridy (PEG-interferon β-1a) / Biogen
Enrollment closed, Enrollment change, Trial primary completion date, Real-world evidence, Real-world effectiveness, Real-world: Plegridy Observational Program (clinicaltrials.gov) - Mar 3, 2017 P=N/A, N=1210, Active, not recruiting, Trial primary completion date: Jun 2017 --> Dec 2017 Recruiting --> Active, not recruiting | N=1600 --> 1210 | Trial primary completion date: Aug 2022 --> Jan 2022
- |||||||||| Plegridy (PEG-interferon β-1a) / Biogen
Trial primary completion date: Biogen Multiple Sclerosis Pregnancy Exposure Registry (clinicaltrials.gov) - Feb 12, 2017 P=N/A, N=750, Recruiting, Recruiting --> Active, not recruiting | N=1600 --> 1210 | Trial primary completion date: Aug 2022 --> Jan 2022 Trial primary completion date: Dec 2023 --> Jun 2028
- |||||||||| Plegridy (PEG-interferon β-1a) / Biogen
Enrollment change, Trial termination, Trial primary completion date: Single Center, Open Label, Study of Preparation H on Erythema in Relapsing MS Patients Treated With PLEGRIDY (clinicaltrials.gov) - Sep 28, 2016 P=N/A, N=32, Terminated, Initiation date: Feb 2016 --> Oct 2016 N=40 --> 32 | Recruiting --> Terminated | Trial primary completion date: Dec 2016 --> Sep 2016; It was decided on 9/21/2016 to terminate this study early because LogPad devices the patients used to record their injection data was flawed
- |||||||||| Betaseron (IFN-β-1b) / Bayer
Enrollment open: EPID Multiple Sclerosis Pregnancy Study (clinicaltrials.gov) - Sep 27, 2016 P=N/A, N=1671, Recruiting, N=40 --> 32 | Recruiting --> Terminated | Trial primary completion date: Dec 2016 --> Sep 2016; It was decided on 9/21/2016 to terminate this study early because LogPad devices the patients used to record their injection data was flawed Active, not recruiting --> Recruiting
- |||||||||| Betaseron (IFN-β-1b) / Bayer
Clinical: EPID Multiple Sclerosis Pregnancy Study (clinicaltrials.gov) - Jun 20, 2016 P=N/A, N=1671, Active, not recruiting, Active, not recruiting --> Recruiting Not yet recruiting --> Active, not recruiting
- |||||||||| Plegridy (PEG-interferon β-1a) / Biogen
Enrollment change, Trial primary completion date, Real-world evidence, Real-world effectiveness, Real-world: Plegridy Observational Program (clinicaltrials.gov) - Apr 11, 2016 P=N/A, N=1600, Recruiting, N=32 --> 0 | Not yet recruiting --> Withdrawn N=3000 --> 1600 | Trial primary completion date: Nov 2022 --> Aug 2022
- |||||||||| Plegridy (PEG-interferon β-1a) / Biogen
Clinical: PLATINUM: Plegridy Satisfaction Study in Participants (clinicaltrials.gov) - Feb 26, 2016 P4, N=275, Recruiting, N=3000 --> 1600 | Trial primary completion date: Nov 2022 --> Aug 2022 Not yet recruiting --> Recruiting
- |||||||||| Plegridy (PEG-interferon β-1a) / Biogen
Trial completion, Enrollment change: Long-Term Safety and Efficacy Study of Peginterferon Beta-1a (clinicaltrials.gov) - Oct 28, 2015 P3, N=1077, Completed, Initiation date: Jun 2013 --> Oct 2013 Active, not recruiting --> Completed | N=1500 --> 1077
|